Lenalidomide plus dexamethasone prolong survival in newly diagnosed multiple myeloma
December 27, 2013 — NEW YORK (Reuters Health) - In patients with newly diagnosed
multiple myeloma who were unfit for stem cell transplant, a
combination of lenalidomide and dexamethasone improved
progression-free survival better than standard therapy.
Multiple myeloma drug meets goal in late-stage study
December 6, 2013 — ZURICH (Reuters) - An experimental drug from Novartis to
treat multiple myeloma met its primary goal in a late-stage
study, the Swiss drugmaker said on Friday.
Select news items provided by Reuters Health